Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ -- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.
Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly.
Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis.
"Securing Shilpa as our lead investor is a transformative step," said Gaurav Mehta, CEO of Alveolus Bio. "Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated."
"Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market," said Dr. C. Vivek Lal, Founder and CSO, Alveolus Bio.
"Shilpa has always focused on enabling breakthrough biologics," said Vishnukant Bhutada, Managing Director, Shilpa Medicare. "This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development."
The financing round remains open to other strategic investors who share Alveolus Bio's vision of transforming respiratory medicine.
About Shilpa Medicare
Shilpa Medicare is a global pharmaceutical company with capabilities across drug discovery to commercialization, specializing in respiratory therapeutics and biotech innovation. Visit www.vbshilpa.com.
About Alveolus Bio
A Biostack Ventures company, Alveolus Bio is developing first-in-class therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs for COPD, BPD, Pulmonary Fibrosis, Cystic Fibrosis, and more.
This is an auto-published feed from PTI with no editorial input from The Wire.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
NSDL makes a strong debut on bourses, shares jump 17% on Wednesday
Shares of National Securities Depository Limited (NSDL) rose 17 per cent during their trading debut on the BSE on Wednesday. The stock listed at ₹880, a 10 per cent premium to its issue price of ₹800, and ended the session at ₹936. Its ₹4,011 crore IPO was subscribed 41 times. The institutional investor portion was subscribed 104 times, the wealthy investor portion 35 times, the retail investor portion nearly 8 times. The IPO was entirely an offer for sale issue. The selling shareholders included IDBI Bank, National Stock Exchange of India (NSE), and four other institutions. The IPO was necessitated as the Securities and Exchange Board of India (Sebi) norms prohibit any single entity from owning more than 15 per cent stake in any market infrastructure institution. NSDL pioneered the dematerialisation of securities in India. As of March 31, 2025, NSDL is the largest depository in India in terms of the number of issuers, the number of active instruments, the market share in demat value of settlement volume and the value of assets held under custody. However, the firm has lagged behind its rival CDSL in terms of the number of demat accounts opened with it. Sri Lotus Developers stock rallies over 31% in mkt debut Shares of Sri Lotus Developers and Realty, backed by renowned investor Ashish Kacholia, closed the first day of trade with a premium of more than 31 per cent against the issue price of ₹150 on Wednesday. The stock listed at ₹179.10, up by 19.4 per cent from the issue price on the BSE. During the day, the shares of Sri Lotus Developers and Realty surged 31.3 per cent to hit a high of ₹197 apiece. Later, shares settled at ₹196.85, up 31.23 per cent. On the NSE, the stock climbed 18.67 per cent to ₹178 in the initial trade. Later, the shares of the company bounced closed at ₹195.80, up 30.53 per cent, also its upper price band. At the market close, the company's market valuation stood at ₹9,620.53 crore on the BSE. In volume terms, 9.18 crore equity shares were traded on the NSE while 1.69 crore shares changed hands on the BSE, during the day. The ₹792 crore initial public offering (IPO) was subscribed 69.14 times on the final day of bidding on Friday. Sri Lotus Developers on Tuesday raised ₹237 crore from institutional investors. BlueStone Jewellery's public issue to open on Aug 11 BlueStone Jewellery and Lifestyle, which offers contemporary jewellery under its flagship brand 'BlueStone', on Wednesday fixed a price band of ₹492 to ₹517 per share for its initial public offering (IPO) .The company's maiden public issue will be open for subscription from August 11 to August 13, according to a IPO involves a fresh issue of ₹820 crore and offer for sale (OFS) of 1,39,39,063 equity shares worth ₹720.65 crore, at the upper end of the price band. Proceeds from the fresh issue will be used for its working capital requirements. Prestige Hospitality Ventures, 4 others get nod to go public As many as five companies, including Prestige Hospitality Ventures and Anand Rathi Share and Stock Brokers, have received Sebi's go ahead to raise funds through initial public offerings (IPOs), an update with the markets regulator showed on that received regulatory clearance are SSF Plastics India, Gujarat Kidney and Super Speciality, and EPack Prefab Technologies. These companies, which filed their preliminary IPO papers between January and April, obtained Sebi's observations during the week, as per the update.
The Hindu
2 hours ago
- The Hindu
Divi's Q1 net up 27% YoY to ₹545 crore, slips sequentially
Active pharmaceutical ingredient (API) manufacturer Divi's Laboratories reported consolidated net profit for June quarter increased nearly 27% to ₹545 crore compared with ₹430 crore a year earlier. The net profit came on an almost 14% increase in the revenue from operations to ₹2,410 crore (₹2,118 crore). Sequentially, however, both the net profit and revenue from operations declined. The company, which specialises in generic APIs, custom synthesis and nutraceuticals, had for the March quarter posted ₹662 crore net profit and ₹2,585 crore revenue from operations. Divi's shares on Wednesday closed 4.29% lower to ₹6,134.25 each on the BSE.
Economic Times
3 hours ago
- Economic Times
Hero MotoCorp reports nominal Q1 PAT growth despite lower sales, beats Street estimates
The country's largest two-wheeler maker Hero MotoCorp Wednesday beat street estimates to report a nominal growth in net profit at Rs 1125.70 crore despite lower sales for the first quarter ended June 30, 2025. ADVERTISEMENT The company had posted net profit of Rs 1122.63 crore in the corresponding period of the last financial year. Brokerage firm Motilal Oswal had expected the company to report 7% decline in net profit for the first quarter ended on back of weak volumes. Motilal Oswal also expected Hero MotoCorp to report 60 bps margin decline to 13.8%, citing a higher EV mix and weak ICE (internal combustion engine) sales. Revenues from operations in the period under review stood at Rs 9578.86 crore, which is a drop of 5.6% over Rs 10143.73 crore in Q1FY25. Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) last quarter stood at Rs 1382 crore. EBITDA margin remained flat at 14.4%. The company sold 13.67 lakh two-wheelers last quarter, which is a decline of 10.9% over 15.35 lakh units sold in the year-ago period. Vivek Anand, Chief Financial Officer, Hero MotoCorp, said, 'Our profitability and margins remained resilient, supported by strong demand for our entry & deluxe motorcycles and 125cc scooter segments. We are witnessing good traction in our electric mobility business (VIDA), and global operations also remained ahead of industry, reflecting the strength of our brand in international markets.' ADVERTISEMENT 'With favourable customer sentiment, upcoming festive season and a robust pipeline of new product launches, we are confident of sustaining and driving growth in the coming quarters', Anand added. Shares of Hero MotoCorp closed at Rs 4,474.50 apiece, down by 1.49% on BSE. The benchmark index fell by 0.21% to 80,543.99 Wednesday. The results were announced after market hours. ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
